BridgeBio Oncology Therapeutics (BBOT) Other Non-Current Assets (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Other Non-Current Assets of $132000.0 for Q1 2026, down 98.95% sequentially from $12.6 million in Q4 2025.
BridgeBio Oncology Therapeutics (BBOT) Other Non-Current Assets (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Other Non-Current Assets for 3 years, with the latest figure at $132000.0 in Q1 2026.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $132000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132000.0 (changed N/A YoY) and the FY2025 annual result came in at $12.6 million, up 9420.45% from the prior year.
- Other Non-Current Assets slipped to $132000.0 in Q1 2026 per BBOT's latest filing, from $12.6 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $12.6 million in Q4 2025 and troughed at $132000.0 in Q4 2024.
- A 3-year average of $3.7 million and a median of $212508.0 in 2024 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 9420.45% in 2025, down 9420.45% in 2025.
- Over 3 years, Other Non-Current Assets stood at $132000.0 in 2024, then surged by 9420.45% to $12.6 million in 2025, then plunged by 98.95% to $132000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $132000.0, $12.6 million, and $5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 12.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.80 Mn |
| Mar 31, 2026 | 132,000.00 |
| Dec 31, 2025 | 12.57 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Dec 31, 2024 | 132,000.00 |
| Mar 31, 2024 | 212,508.00 |